25 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
of the United Kingdom from the European Union, the Russian invasion of Ukraine, the war in the Middle East and other political tensions, and foreign … in Translational Lung Cancer Research. We expect to pursue CE marking of CyPath® Lung for sale in the European Union.
We conducted market research
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
, supply chain weaknesses, instability in the geopolitical environment as a result of the withdrawal of the United Kingdom from the European Union … in the European Union.
We conducted market research in the U.S. with pulmonologists, oncologists, cardiothoracic surgeons, radiologists, and internists engaged
8-K
EX-10.1
BIAF
BioAffinity Technologies Inc
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary
DRS
w6xfxmu
14 Aug 23
Draft registration statement
12:00am
8-K
EX-99.1
bw8to
15 May 23
Results of Operations and Financial Condition
12:22pm
10-K
3olt0mit36e667 rn7x7
31 Mar 23
Annual report
3:40pm
8-K
EX-1.1
eml0wu8 2rdn
6 Sep 22
Entry into a Material Definitive Agreement
1:15pm
424B4
vob3wyv
2 Sep 22
Prospectus supplement with pricing info
3:25pm